CAR T-Cell Therapy Gets a Reality Check--New Guidelines for Europe and Asia-- Off-Beat Cancer Research

myelomaMinBanner2.8.png

| INNOVATION | Latest Research

2.8Blog490x245.png

A Reality Check for CAR T-Cell Therapy

Do our expectations for CAR T-cell therapy outweigh the facts? IMF Chairman Dr. Brian G.M. Durie analyzes a newly published study, comparing it with results from studies of more conventional treatments. Also, a look at updated myeloma guidelines from Europe and Asia.

LearnMoreButton.png

| ACTION | Fundraiser

wineFundraiser.jpg

| INSPIRATION | Fundraiser

valentines200.png

Great Wine + Great Causes

Amazon Valentine's Day

Brady and Christen Raanes’ (c)3 Wines sources grapes from the best vineyards in the world, with the mission of passing all profits to charitable organizations. Purchase a bottle and profits will benefit the IMF. Cheers!

Planning to give a gift to a special someone this Valentine’s Day? Here’s how to double the good you do. When you shop at amazon.myeloma.org, Amazon will donate a percentage of your total purchase to the IMF - at no added cost to you.

GetInvolvedButton.png

ShopNowButton.png

| EMPOWERMENT | Survey 

Survey490.png

New Year: New Look

You may have noticed the Myeloma Minute recently underwent a redesign. We want to know what you think! Please take a few minutes to answer this short survey and let us know.

TakeSurveyButton.png

| INNOVATION | Latest Research 

Xray490x245.png

International Trial Demonstrates Non-Inferiority of Denosumab for Bone Problems in Myeloma

The results of a large (1,718 patients) international trial published today in Lancet Oncology demonstrate the non-inferiority of denosumab (a monoclonal antibody) versus zoledronic acid (Zometa®, a bisphosphonate similar to Aredia®) in reducing bone problems for myeloma patients. “Of note, renal issues were less with denosumab, so this can be considered as the preferred option in the setting of any kidney impairment,” says IMF Chairman Dr. Brian G.M. Durie, a study co-author. “Denosumab also has the advantage of being a shot versus the IV infusion of Zometa.” Patients should discuss potential use with their treating physician with regard to both benefits and reimbursement, he says.

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox2.8.png

CLINICAL TRIALS

EVENTS

BOSTON Trial Fact Sheet

New selinexor STORM Trial: Learn How to Participate

New ARROW Clinical Trials: Learn How to Participate

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

February 9-10, 2018
IMF Patient & Family Seminar
San Francisco, CA

February 25, 2018
Multiple Myeloma Symposium
Kingston, Jamaica

March 10, 2018
IMF Regional Community Workshop
Denver, CO

March 10, 2018
2nd Annual Masters Tennis for Myeloma
The Villages, FL

March 16-17, 2018
IMF Patient & Family Seminar
Boca Raton, FL

April 8, 2018
Julianne’s Rock n’ Roll Half-Marathon
San Francisco, CA

April 21, 2018
IMF Regional Community Workshop
Nashville, TN

 

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year